Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

6,401.00GBp
20 Mar 2019
Change (% chg)

-- (--)
Prev Close
6,401.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,114,889
52-wk High
6,467.00
52-wk Low
4,746.00

Select another date:

Tue, Feb 26 2019

Photo

AstraZeneca's Lynparza meets main goal in late-stage pancreatic cancer study

British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for a rare type of pancreatic cancer.

AstraZeneca's Lynparza meets main goal in late-stage pancreatic cancer study

British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for a rare type of pancreatic cancer.

UPDATE 1-AstraZeneca's Lynparza meets main goal in late-stage pancreatic cancer study

Feb 26 British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for a rare type of pancreatic cancer.

AstraZeneca's Lynparza meets main goal of late-stage cancer study

Feb 26 British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for pancreatic cancer.

New cancer drugs, China give AstraZeneca welcome sales boost

Drugmaker AstraZeneca forecast a second straight year of sales growth on Thursday, driven by revenue from cancer medicines and other new treatments, lifting its shares.

New cancer drugs, China give AstraZeneca welcome sales boost

Drugmaker AstraZeneca forecast a second straight year of sales growth on Thursday, driven by revenue from cancer medicines and other new treatments, lifting its shares.

UPDATE 3-New cancer drugs, China give AstraZeneca welcome sales boost

* Shares up 5 pct, on track for best day in over 18 months (Adds details , CEO comments, share move)

CORRECTED-AstraZeneca, Micro Focus lift FTSE 100; midcap ConvaTec sinks

Feb 14 Britain's main index on Thursday held onto a more than four-month high hit in the last session, aided by earnings-driven gains in drugmaker AstraZeneca and software firm Micro Focus and boosted by forecast-beating trade data from China.

UPDATE 1-AstraZeneca tops sales forecasts, stays calm on Brexit

Feb 14 British drugmaker AstraZeneca Plc beat expectations for product sales in the fourth quarter and forecast a second consecutive year of growth, driven by gains in emerging markets including China and demand for its new cancer medicines.

AstraZeneca product sales top forecasts with 8 pct rise

Feb 14 British drugmaker AstraZeneca Plc reported an 8 percent rise in product sales for the fourth quarter on Thursday, beating analysts' expectations on the back of strong demand for newer drugs including cancer medicines.

Select another date: